NCT05646264 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A
Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry. 2006 Jun 1;59(11):1087-96. doi: 10.1016/j.biopsych.2005.11.025. Epub 2006 Feb 24.
Englisch S, Jung HS, Lewien A, Becker A, Nowak U, Braun H, Thiem J, Eisenacher S, Meyer-Lindenberg A, Zink M
Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study. J Cli

A Real World Study on the Efficacy and Safety of Agomelatin Combined With Second Generation Antipsychotics in the Treatment of Negative Symptoms in Patients With Schizophrenia

Details for clinical trial NCT05646264

Clinical trial NCT05646264 - References